HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Status:
Recruiting
Trial end date:
2023-08-10
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, multicenter study to evaluate the efficacy and safety
of HX008 injection combined with irinotecan versus placebo combined with irinotecan as
second-line therapy in patients with adcanced gastric or gastroesophageal junction (GEJ)
adenocarcinoma who have had tumor progression after first-line treatment with platinum and/or
fluropyrimidine therapy.